February 11, 2016
Compared with placebo, losartan had no effect on cardiac function or exercise capacity and failed to slow down the progression of disease in patients with overt hypertrophic cardiomyopathy, according to results of the INHERIT study published in Heart.
Anna Axelsson, MD, of the department of cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Denmark, and colleagues conducted a randomized, double blind, single-center, placebo-controlled study from 2011 to 2014 to assess the efficacy of losartan as a disease modifier in patients with hypertrophic cardiomyopathy. One hundred thirty-three adult patients with overt hypertrophic cardiomyopathy were randomly assigned 100 mg losartan daily (n = 64) or matching placebo (n = 69) for 12 months. Patient compliance was 93% at the end of the study.